Alexandra Mayer-Da-Silva

Alexandra Mayer-Da-Silva

Auto-generated profile, based on publicly available information

Alexandra Mayer-Da-Silva

Southern Portugal Cancer Registry, Portuguese Oncology Institute of Lisbon Francisco Gentil, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in The Breast
Verified
Journal Article
Open access
FBFábio Cardoso Borges
Fábio Cardoso Borges
FCFilipa Costa
Filipa Costa
ARAdriana Ramos
Adriana Ramos
CRCatarina Ramos
Catarina Ramos
CBCatarina Bernardo
Catarina Bernardo
ALAntónio Lourenço
António Lourenço
Real-world (RW) data may provide valuable information on the effectiveness and safety of medicines, which is particularly relevant for clinicians, patients and third-party payers. Evidence on the effectiveness of palbociclib plus fulvestrant is scarce, which highlights the need of additional studies. The aim of this study was to evaluate the effectiveness of palbociclib plus fulvestrant in advanced breast cancer (ABC). We conducted a population-based retrospective cohort study and cases of interest were identified through the Portuguese National Cancer Registry database and additional data sources. Patients aged≥18 years, diagnosed with ABC and exposed to palbociclib plus fulvestrant between May 31, 2017 and March 31, 2019 were included. Patients were followed-up until death or cut-off date (February 28, 2021). Primary outcome was rw-progression-free survival (rwPFS). Secondary outcomes were rw-overall survival (rwOS), rw-time to palbociclib failure (rwTPF) and rw-time to next treatment (rwTTNT). A total of 210 patients were included. Median age was 58 years (range 29–83) and 99.05% were female. Median follow-up time was 23.22 months and, at cut-off date, treatment had been discontinued in 189 patients, mainly due to disease progression (n = 152). Median rwPFS was 7.43 months (95% confidence interval [CI] 6.28–9.05) and 2-year rwPFS was 16.65% (95%CI 11.97–22.00). Median rwOS was 24.70 months (95%CI 21.58–29.27), median rwTPF was 7.5 months (95%CI 6.51–9.08) and median rwTTNT was 11.74 months (95%CI 10.33–14.08). Palbociclib plus fulvestrant seems an effective treatment for ABC in real-world context. Compared to registrations studies, rwPFS and rwOS were shorter in real-life setting.

5 June 2023 in Annals of Global Health
Verified
Journal Article
Open access
PDF file
TGTeresa Guerreiro
Teresa Guerreiro
AMAlexandra Mayer
Alexandra Mayer
PAPedro Vargues Aguiar
Pedro Vargues Aguiar
AAAntónio Araújo
António Araújo
CNCarla Nunes
Carla Nunes
Background: Timeliness of care is an important dimension of healthcare quality but it’s unclear whether it improves clinical outcomes in lung cancer (LC) patients. Objectives: This study aims to analyze treatment patterns, time-to-treatment (TTT) and the impact of treatment timeliness (TT) in overall survival (OS) of patients diagnosed with LC in 2009–2014 in a population-based registry from Southern Portugal. Materials and Methods: We estimated median TTT for overall population, treatment type and stage. The impact of treatment and TT on five-year OS was analyzed using the Kaplan-Meier method and Cox regression modelling to determine the hazard ratio (HR) of death associated with treatment and TT. Results: From the 11,308 cases diagnosed, 61.7% received treatment. Treatment rate decreased with increasing stage from 88% in stage I to 66.1% in stage IV. Overall median TTT was 49 days (IQR: 28–88) and 43.3% received TT. Surgery had a longer TTT than radiotherapy and systemic treatment. Patients in earlier stages had lower TT rates and longer TTT compared to more advanced, 24.7% and 80 days in stage I versus 51.3% and 42 days in stage IV (p < 0.0001). OS was 14.9% for total population and 19.6% and 7.1% for patients with and without treatment registered, respectively. TT had no observed impact on OS for stages I/II but a negative effect for stages III/IV. Relative to treated, the adjusted mortality risk was higher in untreated patients (HR = 2.240; 95%CI: 2.293–2.553). Contrary to treatment, TT had a negative impact on survival, with 11.3% in timely vs. 21.5% in untimely treated. Compared to untimely treated, the risk of death in TT patients was 46.6% higher (HR = 1.465; 95%CI: 1.381–1.555). Conclusions: LC survival is highly dependent on early diagnosis and adequate treatment. Time-to-treatment was longer than recommended for all treatment types but particularly for surgery. Overall TT results were paradoxical, as better survival was observed in patients untimely treated. The factors associated with TT were not possible to analyze and its impact on patient outcomes remains unclear. However, it is important to assess quality-of-care to improved LC management.

11 June 2025 in European Journal of Cancer
Verified
Journal Article
Open access
ATAnnalisa Trama
Annalisa Trama
SRSilvia Rossi
Silvia Rossi
DBDamien Bennet
Damien Bennet
CSCharles Stiller
Charles Stiller
KPKeiu Paapsi
Keiu Paapsi
LBLaura Botta
Laura Botta
In Europe, cancer survival rates are high and improving for children (0-14 years) and AYAs (15-39 years). However, AYAs often have worse outcomes than children but better than adults. Using EUROCARE data, this study analyzes 5-year relative survival rates across age groups, highlighting age-specific differences and survival trends over time to address persistent disparities. Data were collected from 95 European population-based cancer registries, covering 57 % of the European population. Analyses included malignant cancers diagnosed between 2006 and 2013. Five-year RS was estimated using the period approach for follow-up between 2010 and 2014. Comparisons between AYAs, children, and adults (40-69 years) were conducted using the Z test for absolute differences. Changes in survival trends over time were analyzed from 2004 to 2013 using the Average Annual Percentage Change (AAPC). AYAs had lower 5-year RS than children for hematologic cancers, particularly acute lymphoblastic leukemia (61 % vs. 90 %) and Ewing sarcoma (51 % vs. 69 %). Survival gaps were smaller for central nervous system tumors, germ cell cancers, and thyroid carcinoma. Compared to adults, AYAs had higher 5-year RS for most cancers, except breast, colon, and prostate cancers. Over time, 5-year RS improved across all age groups, with AYAs showing faster improvement than children but slower progress compared to adults for certain cancers. Age-specific disparities in cancer survival persist despite overall improvements. Tailored treatment approaches, specialized AYA oncology programs and collaboration between pediatric and adult oncologists are crucial to bridging survival gaps and improving outcomes for this population.

19 October 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
Emanuele CrocettiEmanuele Crocetti
Emanuele Crocetti
DBDamien Bennett
Damien Bennett
VJValerie Jooste
Valerie Jooste
SRSilvia Rossi
Silvia Rossi
LMLuigino DAL MASO
Luigino DAL MASO
GGGemma Gatta
Gemma Gatta

10 November 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MBMargarida Brito
Margarida Brito
MRMarco Ramos
Marco Ramos
JSJosé Pais Silva
José Pais Silva
GCGabriela Câmara
Gabriela Câmara
AMAlexandra Mayer
Alexandra Mayer
SESusana Esteves
Susana Esteves

19 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
LBLaura Botta
Laura Botta
RCRiccardo Capocaccia
Riccardo Capocaccia
CVClaudia Vener
Claudia Vener
ABAlice Bernasconi
Alice Bernasconi
ATAnnalisa Trama
Annalisa Trama
VJValerie Jooste
Valerie Jooste
Adolescents and young adults (AYAs), aged 15-39, face unique challenges as cancer survivors, including long-term health issues treatment. This study applies a novel approach to estimate the relative risk (RR) of mortality from non-cancer causes in AYA cancer patients compared to the general population and the cure fraction (CF) for AYA patients. Conventional and new mixture cure models with various parametric survival functions were applied to the most common AYA cancers. EUROCARE-6 cases diagnosed between 1998 and 2002, with follow-up to 2014, were selected. Qualitative and quantitative criteria were used to select the optimal model. CFs and RRs were estimated by cancer type, age group, and sex. RRs> 1 were found in both sexes for leukaemia, chronic myeloid leukaemia, lymphoma, central nervous system (CNS) tumours, and skin melanoma, and for testicular germ cell, breast and cervix cancers, with RR generally higher in younger patients and decreasing with age. For acute myeloid leukaemia, colorectal cancer, bone sarcoma for both sexes and soft tissue sarcoma, acute lymphoblastic leukaemia (ALL), and ovary germ cell in females, there was no indication for extra risk. Higher CFs were found in adolescents compared to older AYAs (30-39 years), especially for ALL, CNS tumours in males, and colorectal cancer in females. Further studies are needed to understand why RRs are elevated in AYA patients, to investigate comorbidities and side effects of treatment. Accurate estimation of cancer mortality and CF is vital for resource allocation, tailored follow-up care, and imporving patient quality of life.